TESARO Inc (NASDAQ:TSRO) Successfully Achieves Primary And Secondary Endpoints In Final Phase 3 Trial Of Rolapitant

Boston, MA 05/12/2014 (wallstreetpr) –  TESARO Inc (NASDAQ:TSRO) said that its researched-drug satisfied the main goal in a “delayed-stage Phase 3 trial”. Its experimental drug was developed for the impediment of chemotherapy-induced nausea and vomiting (CINV). It is undeniably excellent news for the cancer patients who bear the pain of chemotherapy regularly. The company developed […]

TESARO Inc. (NASDAQ:TSRO) enters into Partnership for clinical trials

Boston, MA 06/04/2013 (wallstreetpr) – The share prices of TESARO Inc. (NASDAQ:TSRO) had surged by whopping 35.11 percent to close at $46.22 per share for the end of last trading session on Monday. The shares of the development stage, oncology focused pharmaceutical company had been trading in the range of $34.45 to $47.50 per share during […]

TESARO INC. (NASDAQ:TSRO) appoints new BOD

Boston, MA 05/17/2013 (wallstreetpr) – The oncology based bio-pharmaceutical company, TESARO Inc. (NASDAQ:TSRO) had surged in share prices by 14.09 percent to $35.88 by the close of trading session. The share prices reached an all time high of $36.80 which resulted in the adjustment of 52 week high price to the new value. The bio-pharmaceutical […]